EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
LENZ Therapeutics, Inc. (LENZ) had EBIT Margin of -337.14% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$5.00M |
|
$-14.91M |
|
-- |
|
$5.00M |
|
$21.86M |
|
$-16.86M |
|
$2.44M |
|
$-14.41M |
|
$-14.41M |
|
$-14.91M |
|
$-14.91M |
|
$-14.91M |
|
$-14.91M |
|
$-16.86M |
|
$-17.73M |
|
28.08M |
|
28.08M |
|
$-0.53 |
|
$-0.53 |
|
| Balance Sheet Financials | |
$213.60M |
|
$1.17M |
|
$3.73M |
|
$217.33M |
|
$10.40M |
|
-- |
|
$0.57M |
|
$10.97M |
|
$206.37M |
|
$206.37M |
|
$206.37M |
|
28.50M |
|
| Cash Flow Statement Financials | |
$-27.56M |
|
$18.48M |
|
$26.53M |
|
$20.27M |
|
$37.72M |
|
$17.45M |
|
$5.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
20.54 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-337.14% |
|
|
EBIT Margin |
-337.14% |
-- |
|
-288.24% |
|
-298.24% |
|
$-27.91M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-7.23% |
|
-7.23% |
|
-6.86% |
|
-7.23% |
|
$7.24 |
|
$-0.99 |
|
$-0.98 |
|